Presentations and Publications

Prior to August 2023, CervoMed was known as EIP Pharma, the name utilized in prior publications from the company.

April 2024 | CervoMed

CervoMed in BioCentury

BioCentury | Selina Koch

October 2023 | CervoMed

Drug development targeting degenerationof the basal forebrain cholinergic system: its time has come

Molecular Neurodegenration | Alam, et al.

September 2020 | EXTERNAL EXPERTS

Functions of p38 MAP Kinases in the Central Nervous System

Frontiers in Molecular Neuroscience | Asih, et al.

July 2020 | CervoMed

P38α MAPK Signaling—A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease

International Journal of Molecular Sciences | Alam, et al.


Associations of MAP2K3 Gene Variants With Superior Memory in SuperAgers

Frontiers in Aging Neuroscience | Huentelman, et al.

December 2017 | EXTERNAL EXPERTS

Forecasting the Prevalence of Preclinical and Clinical Alzheimer’s Disease in the United States

Alzheimer’s & Dementia | Brookmeyer, et al.


Glucose Deficit Triggers Tau Pathology and Synaptic Dysfunction in a Tauopathy Mouse Model

Translational Psychiatry | Lauretti, et al.

December 2016 | EXTERNAL EXPERTS

Selective Suppression of the α Isoform of p38 MAPK Rescues Late-Stage Tau Pathology

Alzheimer’s Research & Therapy | Maphis, et al.

September 2015 | EXTERNAL EXPERTS

Synapse-Specific IL-1 Receptor Subunit Reconfiguration Augments Vulnerability to IL 1β in the Aged Hippocampus

Proceedings of the National Academy of Sciences of the United States of America | Prieto, et al.

About CervoMed

Are you a patient, caregiver, clinician or professional and want to learn more about CervoMed’s approach? Please contact us.

Contact Us